Sun Pharmaceutical Industries has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma’s specialty focus areas.
Under the terms of the license agreement, the company gets exclusive global license for the said patents and any other future patents covered in the agreement. The company will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totaling up to Rs 2.40 billion, plus royalties on net sales from commercialization of the products developed using these patents. The company will be responsible for development, regulatory filings, manufacturing and commercialization of these potential products.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1905.00 |
| Dr. Reddys Labs. | 1370.35 |
| Cipla | 1457.05 |
| Zydus Lifesciences | 1139.60 |
| Lupin | 2479.95 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: